LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Moderate Buy” by Analysts

LifeMD, Inc. (NASDAQ:LFMD) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.1429.

Several research firms recently issued reports on LFMD. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of LifeMD in a research report on Monday, May 4th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research report on Tuesday, May 26th. Finally, Zacks Research lowered shares of LifeMD from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.71 on Monday. The firm has a market cap of $179.42 million, a P/E ratio of 74.21 and a beta of 1.99. LifeMD has a fifty-two week low of $2.56 and a fifty-two week high of $12.72. The business has a 50-day moving average price of $4.51 and a 200 day moving average price of $3.99.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The firm had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. As a group, equities research analysts anticipate that LifeMD will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On LifeMD

Large investors have recently bought and sold shares of the business. Whetstone Capital Advisors LLC grew its holdings in shares of LifeMD by 89.6% during the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after purchasing an additional 332,269 shares during the last quarter. Prescott Group Capital Management L.L.C. acquired a new stake in shares of LifeMD during the 4th quarter worth approximately $2,344,000. MYDA Advisors LLC bought a new stake in shares of LifeMD in the 4th quarter worth approximately $512,000. State of Wyoming lifted its holdings in shares of LifeMD by 146.9% in the 1st quarter. State of Wyoming now owns 142,499 shares of the company’s stock worth $514,000 after purchasing an additional 84,785 shares during the last quarter. Finally, R Squared Ltd acquired a new position in LifeMD during the 1st quarter valued at approximately $41,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.